Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Phytomedicine. 2022 Aug;103:154224. doi: 10.1016/j.phymed.2022.154224. Epub 2022 May 30.
Xuesaitong injection (XST), a well-known traditional Chinese patent medicine, has been widely used in the treatment of cardiovascular and cerebrovascular diseases. The exact mechanisms of XST in ischemic stroke remain to be thoroughly elucidated.
This study aims to characterize the candidate differentially expressed genes (DEGs) and pathways of XST in ischemic stroke by bioinformatics analysis, and to explore new clues for the underlying mechanisms of XST.
A dataset (GSE61616) was performed to screen out DEGs for deep analysis. Series Test of Cluster analysis for DEGs was carried out. For all DEGs, Gene Ontology (GO) annotation analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for visualization. The screened hub gene expression characteristics were verified in middle cerebral artery occlusion (MCAO) rats. In vivo studies have demonstrated the mechanisms of XST against cerebral ischemia-reperfusion (CIR) injury.
A total of 8066 DEGs were screened out and the expression of genes in profile 8 was suggested to have clinical significance. The MAPK signaling pathway was indicated as the most significantly enriched pathway in profile 8. Bdnf was identified as the most significant hub gene according to node degree. Animal experiments demonstrated that XST attenuated CIR injury. XST increased brain-derived neurotrophic factor (BDNF) and its high-affinity receptor tropomyosin-related kinase B (TrkB) levels in MCAO. Furthermore, the knockdown of BDNF by siRNA abolished the in vivo effects of XST on brain injury, neurodegeneration and apoptosis after CIR.
The integrated strategy, based on bioinformatics analyses with experimental verification, provides a novel cellular mechanism by which XST alleviates CIR injury. The BDNF-TrkB pathway was highly thought to play a vital role in the neuroprotective effects of XST.
血塞通注射液(XST)是一种著名的中药专利药物,已广泛用于治疗心血管和脑血管疾病。XST 治疗缺血性中风的确切机制仍需深入阐明。
本研究旨在通过生物信息学分析,对 XST 治疗缺血性中风的候选差异表达基因(DEG)和途径进行表征,并探索 XST 潜在机制的新线索。
对数据集(GSE61616)进行分析,筛选出 DEG 进行深入分析。对所有 DEG 进行基因本体论(GO)注释分析和京都基因与基因组百科全书(KEGG)通路富集分析,以进行可视化处理。在大脑中动脉闭塞(MCAO)大鼠中验证筛选出的核心基因表达特征。体内研究表明了 XST 对抗脑缺血再灌注(CIR)损伤的机制。
共筛选出 8066 个 DEG,提示谱 8 中的基因表达具有临床意义。MAPK 信号通路被认为是谱 8 中最显著富集的通路。根据节点度,BDNF 被确定为最显著的核心基因。动物实验表明,XST 减轻了 CIR 损伤。XST 增加了 MCAO 中的脑源性神经营养因子(BDNF)及其高亲和力受体原肌球蛋白相关激酶 B(TrkB)水平。此外,siRNA 敲低 BDNF 可消除 XST 对 CIR 后脑损伤、神经退行性变和细胞凋亡的体内作用。
基于生物信息学分析与实验验证相结合的综合策略,为 XST 减轻 CIR 损伤提供了一种新的细胞机制。BDNF-TrkB 途径被认为在 XST 的神经保护作用中起着至关重要的作用。